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ABSTRACT
A simple and sensitive method was developed to separate the carcinogenic polycyclic aromatic hydrocarbon (PAH), benzo[a]pyrene 
(BaP), and six of its oxidation metabolites generated by rat hepatic microsomes enriched with cytochrome P450 (CYP) 1A1, by high 
pressure liquid chromatography (HPLC). The HPLC method, using an acetonitrile/water gradient as mobile phase and UV detec-
tion, provided appropriate separation and detection of both mono- and di-hydroxylated metabolites of BaP as well as BaP diones 
formed by rat hepatic microsomes and the parental BaP. In this enzymatic system, 3-hydroxy BaP, 9-hydroxy BaP, BaP-4,5-dihydrodiol, 
BaP-7,8-dihydrodiol, BaP-9,10-dihydrodiol and BaP-dione were generated. Among them the mono-hydroxylated BaP metabolite, 
3-hydroxy BaP followed by di-hydroxylated BaP products, BaP-7,8-dihydrodiol and BaP-9,10-dihydrodiol, predominated, while 
BaP-dione was a minor metabolite. This HPLC method will be useful for further defining the roles of the CYP1A1 enzyme with both in 
vitro and in vivo models in understanding its real role in activation and detoxification of BaP.
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associated with developments of cancer, primarily in the 
skin, stomach, and lungs as target tissues (IARC, 1983). BaP 
requires metabolic activation (Figure 1) prior to reaction 
with DNA, which is an essential step in the mechanism, by 
which BaP exerts its genotoxic effects. 
Cytochrome P450 (CYP) enzymes in a combination with 
epoxide hydrolase are the major enzymes activating BaP to 
species binding to DNA. First, the CYP enzymes oxidize 
BaP to form an epoxide that is additionally converted to a 
dihydrodiol by epoxide hydrolase (Baird et al., 2005; Luch 
and Baird, 2005) (Figure 1). Further bioactivation step cata-
lyzed by CYPs leads to the formation of the reactive species, 
benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE) that 
can react with DNA, forming adducts preferentially at 
guanine residues. The 10-(deoxyguanosin-N2-yl)-7,8,9-tri-
hydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene (dG-N2-BPDE) 
adduct is the major adduct formed from BPDE in DNA in 
vitro and in vivo (Phillips, 2005) (Figure 1). Among CYP 
enzymes, CYP1A1 and 1B1 are widely accepted as the most 
important enzymes in such BaP metabolic activation (Baird 
et al., 2005; Luch and Baird, 2005). Nevertheless, controver-
sial results have been found recently in several laboratories, 
showing a more important role of CYP1A1 in vivo in BaP 
detoxification than in its activation (Uno et al., 2004; 2006; 
Introduction
Benzo[a]pyrene (BaP) is the prototype compound of poly-
cyclic aromatic hydrocarbons (PAH). BaP and other PAHs 
are produced mainly by incomplete combustion or pyrolysis 
of organic matter and are ubiquitous in the environment, 
leading to measurable background levels of exposure in 
the general population (IARC, 1983). Beside the inhalation 
of polluted air, the main routes of exposure are through 
tobacco smoke, diet (Phillips, 1999; 2002) and occupational 
exposition throughout, e.g. coal, coke or coal tar process-
ing and use of coal tar products (IARC, 1983). BaP has 
been shown to cause cytotoxic, teratogenic, genotoxic, 
mutagenic, and carcinogenic effects in various tissues and 
cell types in organisms (Nebert, 1989; Ellard et al., 1991). 
Chronic exposure of laboratory animals to BaP has been 
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Arlt et al., 2008). In order to explain such findings, activa-
tion and detoxification metabolism of BaP in vitro and in 
vivo should, therefore, be carefully re-evaluated. For such 
studies, appropriate methods separating and quantifying 
all BaP metabolites generated by CYPs in combination with 
epoxide hydrolase, besides methods evaluating the DNA 
adduct formation by this carcinogen, are necessary. 
A variety of high pressure liquid chromatography 
(HPLC) procedures [reverse phase (RP)-HPLC] separating 
BaP metabolites was described by several authors for the last 
several decades (Selkirk et al., 1974; Selkirk, 1977; Angener 
et al., 1997; Gündel and Angerer, 2000; Hecht, 2001; Sasaki 
et al., 2002; Toriba et al., 2003; Wang et al., 2003; Sagredo et 
al., 2006; Jiang et al., 2007; Zhu et al., 2008). In the 1970´s, 
HPLC was used for separating BaP metabolites combined 
with UV or scintillation counter detection. However, UV 
detection in these studies was not sufficient to detect all 
BaP metabolites (Selkirk, 1977). Therefore, quantitation by 
measuring fluorescence as detection method was devel-
oped (Krahn et al., 1984). However, BaP diones, do not 
exhibit fluorescence, and the method does not quantitate 
individual metabolites prohibiting application of fluores-
cence detection for a detailed study of BaP metabolism. 
Thereafter, on-line or off-line radioactivity detection 
played a major role in the study of BaP metabolism (for 
summary see Zhu et al., 2008). The disadvantages of the 
radioactive method include cost, radiolabeled individual 
metabolites are not available, and it cannot be used for 
the analysis of environmental samples. The improvement 
of chromatographic separation methods have allowed for 
significantly better separation of BaP metabolites during 
the 1990´s (James et al., 1995; 1997; Kim et al., 1998). 
From 2000, HPLC coupled with mass spectrometry was 
introduced in the study of BaP metabolism, though there 
were still problems associated with high detection limits 
for BaP diones (van Schanke et al., 2001). Recently, ultra-
performance liquid chromatography has been introduced 
with improved performance over traditional HPLC (Zhu et 
al., 2008). However, there are still several disadvantages in 
all these methods, predominantly cost of analyses, which 
prohibit them to be suitable for general use in most of labo-
ratories. Therefore, the aim of this study was to improve 
the HPLC procedure to be effective for separation of BaP 
metabolites generated by BaP oxidation with rat hepatic 
microsomes and sensitive enough to be able to detect BaP 
metabolites with UV detection. 
Materials and methods
Chemicals 
Chemicals were obtained from the following sources: 
methanol ( MetOH; HP LC supergradient ) from Lachner 
(Czech Republic); acetonitrile (HPLC grade) from Merck 
(Darmstadt, Germany); benzo[a]pyrene (≥ 96% based on 
HPLC), NADP+, glucose-6-phosphate, phenacetine and 
bicinchoninic acid (2,2´-biquinoline-4,4´-dicarboxylic acid) 
from Sigma Chemical Co. (St. Louis, MO, USA) and glu-
cose-6-phosphate dehydrogenase from Serva (Heidelberg, 
Germany). All these and other chemicals used in the experi-
ments were of analytical purity or better. 
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Figure 1. Metabolic activation and DNA adduct formation by benzo[a]pyrene. The typical three- step activation process 
with contribution of CYP1A1 or CYP1B1 and epoxide hydrolase leads to the formation of the ultimately reactive spe-
cies, benzo[a]pyrene-7,8- dihydrodiol-9,10-epoxide (BPDE) that can react with DNA, forming adducts preferentially at 
guanine residues.241
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Preparation and characterization of microsomes
The animal experiment was conducted in accordance 
with the Regulations for the Care and Use of Laboratory 
A n i m a l s  ( 3 1 1 / 1 9 9 7 ,  M i n i s t r y  o f  A g r i c u l t u r e ,  C z e c h  
Republic), which is in compliance with the Declaration 
of Helsinki. Microsomes from rats pretreated with Sudan 
I were isolated from pooled livers of ten rats as described 
previously (Stiborová et al., 2003). Protein concentration in 
the microsomal fraction was measured using bicinchoninic 
acid protein assay (Wiechelman et al., 1988) with bovine 
serum albumin as a standard. The content of CYPs was 
determined by differential spectroscopy based on utilizing 
a characteristic absorption of the complex of this hemthio-
late protein in reduced state with carbon oxide at 450 nm 
(Omura and Sato, 1964).
Incubations
Incubation mixtures used for studying BaP metabolism 
contained 100 mM sodium phosphate buffer (pH  7.4), 
NADPH-generating system (1  mM NADP+, 10  mM 
D-glucose-6-phosphate, 1  U/ml D-glucose-6-phosphate 
dehydrogenase), 0.5  mg of microsomal protein, 50  μM 
BaP (dissolved in 5  μl methanol) in a final volume of 
500  μl. The reaction was initiated by adding 50  μl of the 
NADPH-generating system. Control incubations were car-
ried out either without enzymatic system (microsomes) or 
without NADPH-generating system or without BaP. After 
incubation in open tubes (37  °C, 20 min), 5  μl of 1  mM 
phenacetine in methanol was added as an internal standard. 
BaP metabolites were extracted twice with ethyl acetate 
(2 × 1  ml) and evaporated to dryness. The samples were 
dissolved in 25 μl methanol and BaP metabolites formed in 
this system separated by HPLC.
HPLC instrument used for HPLC analysis of BaP metabolites
HPLC analyses of BaP metabolites were performed using a 
Dionex system consisting of a Dionex pump P580, a UV/VIS 
Detector UVD 170S/340S, an ASI-100 Automated Sample 
Injector, a termobox COLUMN OVEN LCO 101 and an 
In-Line Mobile Phase Degasser Degasys DG-1210 Dionex 
controlled with Chromeleon™ 6.11 build 490 software. 
Chromatographic separation was performed on two types 
of reversed phase columns, Ultrasphere® ODS, C18, 5 μm, 
250 × 4.6 mm (Beckman-Coulter, USA) and Nucleosil® 
100-5 C18, 5 μm, 250 × 4 mm (Macherey Nagel, Germany). 
Chromatographic conditions 
Four different conditions to separate BaP metabolites were 
used. The first one was analogous to that used by Selkirk et 
al., 1974. Mobile phase A: 30% methanol (30:70 methanol: 
water, v/v), mobile phase B: 70% methanol (70:30 methanol: 
water, v/v), flow rate: 0.6 ml/min at operation temperature of 
35 °C, detection at 254 nm. The 20 μl sample was injected for 
HPLC analysis. BaP metabolite separation was performed 
using a Nucleosil® C18 reverse phase column, (250 × 4 mm, 
5 μm; Macherey Nagel). Linear gradient system started from 
30% methanol to 70% methanol in 33 min and followed by 
isocratic elution of mobile phase B in 32 min (Procedure 1, 
Figure 2A).
In the second procedure (Procedure 2) the same condi-
tions as in Procedure 1 were used except that separation of 
BaP metabolites was performed using an Ultrasphere®, ODS, 
C18 reverse phase column (250 × 4.6 mm, 5 μm) (Figure 2B).
In the Procedure 3 the experimental conditions were as 
follows: mobile phase: 85% acetonitrile (85:15 acetonitrile: 
water, v/v), flow rate: 0.6 ml/min at operation temperature 
of 35 °C, detection at 254 nm. The 20 μl sample was injected 
for HPLC analysis.
BaP metabolite separation was performed using the 
isocratic elution of mobile phase in 55 min, on a Nucleosil® 
C18 reverse phase column, (250 × 4 mm, 5 μm; Macherey 
Nagel) (Figure 3).
In the Procedure 4 the experimental conditions were 
as follows: mobile phase A: 50% acetonitrile (50:50 aceto-
nitrile: water, v/v), mobile phase B: 85% acetonitrile (85:15 
acetonitrile: water, v/v). Initial elution conditions were 50% 
acetonitrile with a linear gradient to 85% acetonitrile in 35 
min, then an isocratic elution of 85% acetonitrile in 5 min, 
a linear gradient from 85% acetonitrile to 50% acetonitrile 
in 5 min, followed by an isocratic elution of 50% acetoni-
trile in 5 min. Total run time was 50 min. BaP metabolite 
separation was performed on a Nucleosil® C18 reverse phase 
column, (250 × 4 mm, 5 μm; Macherey Nagel). The used 
gradient program is shown in Table 1. The BaP metabolite 
peaks (Figure  4) were collected and analyzed by mass 
spectrometry. 
Mass spectrometry
Mass spectra were measured on a matrix-assisted laser 
desorption/ionisation reflectron time-of-flight MALDITOF 
mass spectrometer ultraFLEX (Bruker-Daltonics, Bremen, 
Germany). Positive spectra were calibrated externally using 
the monoisotopic [M+H]+ ion of bradykinin 757.399 m/z and 
CCA matrix peaks 190.050, 379.092 m/z. A 10 mg/ml solu-
tion of α-cyano-4-hydroxy-cinnamic acid or 2,5-dihydro-
benzoic acid in 50% acetonitrile/0.3% acetic acid was used as 
a MALDI matrix. A 0.5 μl of sample dissolved in acetonitrile 
was premixed with a 0.5 μl of the matrix solution on the tar-
get and allowed to dry at ambient temperature. The MALDI-
TOF positive spectra were collected in reflectron mode.
Results and discussion 
In order to receive the BaP metabolites, which are formed 
by a combination of CYP- and epoxide hydrolase-mediated 
reactions, rat hepatic microsomes used in the experiments. 
Because CYP1A1 is one of the most efficient enzymes 
metabolizing BaP in vitro, hepatic microsomes of rats 
treated with a CYP1A1 inducer, Sudan I (Lubet et al., 1983; 
Martínek and Stiborová, 2002; Stiborová et al., 2002), were 
employed. Using such microsomes, formation of a spectrum 
of mono- and di-hydroxylated BaP metabolites as well as 
quinones (diones) of BaP that were found to be formed by 
CYP1A1 with epoxide hydrolase (Baird et al., 2005; Luch 
and Baird 2005) was expected.
To improve the existing HPLC chromatographic method 
analyzing BaP metabolites and to make them sensitive 242
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enough to be detected with UV detection, we investigated 
various elution systems and chromatographic procedures. 
In addition, two different HPLC analytical columns were 
examined to evaluate their efficiencies to separate BaP 
metabolites. The columns Ultrasphere®  and Nucleosil® 
obtained from Beckman-Coulter and Macherey-Nagel, 
respectively, were utilized for such a study. Constant flow 
rate of 0.6 ml/min under 35 °C was used. To detect BaP and 
its metabolites, a spectrum of different wavelengths were 
tested to detect BaP (data not shown). The highest sensitiv-
ity to detect BaP and its metabolites separated by HPLC was 
at 254 nm. Four procedures (Procedures 1, 2, 3 and 4, see the 
Materials and Methods section) were tested in this work.
Because several methods described in the former studies 
used methanol/water or acetonitrile/water as mobile phases 
in HPLC for separation of BaP metabolites, we tested both 
these mobile phases in different arrangements. First we tried 
methanol/water as mobile phase with gradient program 
(30% to 70% methanol), which was analogous to mobile 
phase used previously by Selkirk et al., 1974, but even after 
optimization and using two chromatographic columns 
(Nucleosil® C18 and Ultrasphere® reverse phase columns), we 
were unable to detect any BaP metabolites or even BaP itself 
under these conditions (see Figure 2 showing the results 
found using the Procedures 1 and 2). Chromatographic 
profiles were as almost baseline without elution of BaP and 
metabolites (Figure 2), probably by retaining the BaP and its 
metabolites on the resin under such conditions. 
Since the methanol/water mobile phase was found to be 
inappropriate for elution of BaP and its metabolites, we uti-
lized acetonitrile/water as mobile phase in further studies. 
In this case, we first tried 85% acetonitrile in water (v/v) with 
an isocratic elution using the Nucleosil® C18 reverse phase 
column (Procedure 3), however, even after optimization, we 
did not achieve ideal separation of BaP metabolites formed 
by rat hepatic microsomes (Figure 3). BaP metabolites eluted 
between 4 to 11 min, while BaP at 18.6 min (Figure 3). When 
we changed the elution conditions with acetonitrile/water 
as mobile phase to the gradient program shown in Table 1 
(Procedure 4), six BaP metabolites were almost perfectly 
separated using the same chromatographic column (a 
Nucleosil® C18 reverse phase column, Figure 4). The BaP 
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Figure 2. HPLC separation of the BaP metabolites generated by rat hepatic microsomes using Nucleosil® C18 (A) and Ultrasphere® C18 reverse phase 
columns (B). A linear gradient elution from 30% methanol to 70% methanol in 65 min. Flow rate 0.6 ml/min, UV detection at 254 nm. 
Table 1. HPLC conditions used for a step gradient elution of BaP 
metabolites on a Nucleosil® C18 reverse phase column
Time [min]
Mobile phase A 
50% acetonitrile
Mobile Phase B
85% acetonitrile Flow rate
01 0 0 % 0 %
0.6 ml/min
35 0% 100%
40 0% 100%
45 100% 0%
50 100% 0%243
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metabolites formed by rat hepatic microsomes, assigned in 
Figure 4 as metabolites M1-M6 and eluted at retention times 
of 8.3 (M1), 11.9 (M2), 12.9 (M3), 23.6 (M4), 24.1 (M5) and 
26.1 min (M6), were characterized by mass spectrometry 
and tentatively identified to be BaP-9,10-dihydrodiol (M1), 
BaP-4,5-dihydrodiol (M2), BaP-7,8-dihydrodiol (M3), one of 
the BaP diones (1,6 or 3,6 or 6,12-BaP-dione, M4), 9-hydroxy 
BaP (M5) and 3-hydroxy BaP (M6). Parental BaP was eluted 
at 41 min. The study resolving which of BaP diones is a 
metabolite M4 is under way in our laboratory. 
Conclusion
The new HPLC method developed in this work allows for 
separation of BaP metabolites with increased resolution, 
simple procedure and high detection sensitivity. Because 
of controversial results suggesting a more important role of 
CYP1A1 in vivo in BaP detoxification than in its activation 
(Uno et al., 2004; 2006; Arlt et al., 2008), BaP metabolism 
and DNA adducts formation should be re-investigated in 
more details. The developed HPLC method will be useful 
Figure 3. HPLC separation of the BaP metabolites generated by rat hepatic microsomes using a Nucleosil® C18 reverse phase column. An isocratic 
elution of 85% acetonitrile in 55 min. Flow rate 0.6 ml/min, UV detection at 254 nm. 
Figure 4. HPLC separation of the BaP metabolites generated by rat hepatic microsomes using a Nucleosil® C18 reverse phase column. A linear gradi-
ent elution from 50% methanol to 85% methanol in 50 min. Flow rate 0.6 ml/min, UV detection at 254 nm. PA, phenacetine, M1-M6, BaP metabolites 
[BaP-9,10-dihydrodiol (M1), BaP-4,5-dihydrodiol (M2), BaP-7,8-dihydrodiol (M3), one of the BaP diones (1,6 or 3,6 or 6,12-BaP-dione, M4), 9-hydroxy 
BaP (M5) and 3-hydroxy BaP (M6)]. 
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for such additional studies, to further define the real roles of 
the CYP1A1 enzyme both in vitro and in vivo in activation 
and detoxification of BaP.
Acknowledgement
The research was supported in part Grant Agency of the 
Czech Republic (grants 303/09/0472 and 305/09/H008), 
the Grant Agency of Charles University (grant 127208) and 
the Ministry of Education of the Czech Republic (grant 
MSM0021620808, 1M0505 and RP MSMT 14/63).
REFERENCES
Angerer J, Mannschreck C, Gündel J. (1997). Biological monitoring and bio-
chemical eff  ect monitoring of exposure to polycyclic aromatic hydrocarbons. 
Int Arch Occup Environ Health 70: 365–377.
Arlt VM, Stiborová M, Henderson CJ, Thiemann M, Frei E, Aimová D, Singhs R, da 
Costa GG, Schmitz OJ, Farmer PB, Wolf CR, Phillips DH. (2008). Metabolic acti-
vation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with 
detoxifi  cation in vivo: experim ents with hepatic cytochrome P450 reductase 
null mice. Carcinogenesis 29: 656–665.244
M Moserová, V Kotrbová, D Aimová, M Šulc, E Frei, M Stiborová
HPLC analysis of benzo[a]pyrene metabolites
ISSN: 1337-6853 (print version) | 1337-9569 (electronic version)
Baird WM, Hooven LA, Mahadevan B. (2005). Carcinogenic polycyclic aromatic 
hydrocarbon-DNA adducts and mechanism of action. Environ Mol Mutagen 
45: 106–114.
Ellard S, Mohammed Y, Dogra S, Wolfel C, Doehmer J, Parry JM. (1991). Use of 
genetically engineered V79 Chinese hamster cultures expressing rat liver 
CYP1A1, 1A2 and 2B1 cDNAs in micronucleus assays. Mutagenesis 6: 461–470
Gündel J, Angerer J. (2000). High-performance liquid chromatographic method 
with fl  uorescence detection for the determination of 3-hydroxybenzo[a]py-
rene and 3-hydroxybenz[a]anthracene in the urine of polycyclic aromatic hy-
drocarbon-exposed workers. J Chromatogr B Biomed Sci Appl 738: 47–55.
Hecht SS. (2001). Carcinogen biomarkers for lung or oral cancer chemopreven-
tion trials. IARC Sci Publ 154: 245–255.
IARC Monogr Eval Carcinog Risk Chem Hum. (1983). Polynuclear Aromatic Com-
pounds 32, 211.
James MO, Altman AH, Li CL, Schell JD Jr. (1995). Biotransformation, hepato-
pancreas DNA binding and pharmacokinetics of benzo[a]pyrene after oral 
and parenteral administration to the American lobster, Homarus americanus. 
Chem Biol Interact 95: 141–160.
James MO, Altman AH, Morris K, Kleinow KM, Tong Z. (1997). Dietary modu-
lation of phase 1 and phase 2 activities with benzo(a)pyrene and related 
compounds in the intestine but not the liver of the channel catfi  sh, Ictalurus 
punctatus. Drug Metab Dispos 25: 346–354.
Jiang H, Gelhaus SL, Mangal D, Harvey RG, Blair IA, Penning TM. (2007). Metab-
olism of benzo[a]pyrene in human bronchoalveolar H358 cells using liquid 
chromatography-mass spectrometry. Chem Res Toxicol 20: 1331–1341.
Kim JH, Stansbury KH, Walker NJ, Trush MA, Strickland PT, Sutter TR. (1998). Me-
tabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-diol by human cyto-
chrome P450 1B1. Carcinogenesis 19: 1847–1853. 
Krahn MM, Myers MS, Burrows DG, Malins DC. (1984). Determination of metab-
olites of xenobiotics in the bile of fi  sh from polluted waterways. Xenobiotica 
14: 633–646.
Lubet RA, Connolly G, Kouri RE, Nebert DW, Bigelow SW. (1983). Biological ef-
fects of Sudan I dyes. Role of the cytosolic Ah receptor. Biochem Pharmacol 
32: 3053–3058. 
Luch A, Baird WM. (2005). Metabolic activation and detoxifi  cation of polycyclic 
aromatic hydrocarbons. The Carcinogenic Eff  ects of Polycyclic Aromatic Hydro-
carbons. Imperial College Press, London, 19–96.
Martínek V, Stiborová M. (2002). Metabolism of carcinogenic azo dye Sudan I by 
rat, rabbit, minipig and human hepatic microsomes. Collect Czech Chem Com-
mun 67: 1883–1898. 
Nebert DW. (1989). The Ah locus: genetic diff  erences in toxicity, cancer, muta-
tion and birth defects. Crit Rev Toxicol 20: 153–174.
Omura T, Sato R. (1964). The carbon monoxide-binding pigment of liver micro-
somes. II. Solubilization, purifi  cation, and properties. J Biol Chem 239: 2379–85 
Phillips DH. (1999). Polycyclic aromatic hydrocarbons in the diet. Mutat Res 443: 
139–47.
Phillips DH. (2002). Smoking-related DNA and protein adducts in human tissues 
Carcinogenesis 23: 1979–2004
Phillips DH. (2005). Macromolecular adducts as biomarkers of human exposure 
to polycyclic aromatic hydrocarbons. The Carcinogenic Eff  ects of Polycyclic Aro-
matic Hydrocarbons. Imperial College Press, London, 137–169.
Sagredo C, Øvrebø S, Haugen A, Fujii-Kuriyama Y, Baera R, Botnen IV, Mollerup 
S. (2006). Quantitative analysis of benzo[a]pyrene biotransformation and ad-
duct formation in Ahr knockout mice. Toxicol Lett 167: 173–182. 
Sasaki H, Yonekubo J, Kanai M, Toriba A, Kizu R, Hayakawa K. (2002). Simulta-
neous detection of monohydroxybenzo[a]pyrene positional isomers by re-
versed-phase liquid chromatography coupled to electrospray ionization 
mass spectrometry. Biomed Chromatogr 16: 432–436.
Selkirk JK, Croy RG, Gelboin HV. (1974). Benzo[a]pyrene metabolites: effi   cient and 
rapid separation by high-pressure liquid chromatography. Science 184: 169–171.
Selkirk JK. (1977). Benzo[a]pyrene carcinogenesis: a biochemical selection 
mechanism. J Toxicol Environ Health 2: 1245–1258.
Stiborová M, Martínek V, Rýdlová H, Hodek P, Frei E. (2002). Sudan I is a poten-
tial carcinogen for humans: Evidence for its metabolic activation and detoxi-
cation by human recombinant cytochrome P450 1A1 and liver microsomes. 
Cancer Res 62: 5678–5684.
Stiborová M, Stiborová-Rupertová M, Bořek-Dohalská L, Wiessler M, Frei E. 
(2003). Rat microsomes activating the anticancer drug ellipticine to species 
covalently binding to deoxyguanosine in DNA are a suitable model mimick-
ing ellipticine bioactivation in humans. Chem Res Toxicol 16: 38–47.
Toriba A, Nakamura H, Chetiyanukornkul T, Kizu R, Makino T, Nakazawa H, Yokoi 
T, Hayakawa K. (2003). Method for determining monohydroxybenzo[a]pyrene 
isomers using column-switching high-performance liquid chromatography. 
Anal Biochem 312: 14–22.
Uno S, Dalton TP, Derkenne S, Curran CP, Miller ML, Shertzer HG, Nebert DW. 
(2004). Oral exposure to benzo [a] pyrene in the mouse: detoxication by in-
ducible cytochrome P450 is more important than metabolic activation. Mol 
Pharmacol 65: 1225–37.
Uno S, Dalton TP, Dragin N, Curran CP, Derkenne S, Miller ML, Shertzer HG, Gon-
zalez FJ, Nebert DW. (2006). Oral benzo[a]pyrene in Cyp1 knockout mouse 
lines: CYP1A1 important in detoxication, CYP1B1 metabolism required for im-
mune damage independent of total-body burden and clearance rate. Mol 
Pharmacol 69: 1103–14.
van Schanke A, Holtz F, van der Meer JP, Boon JP, Ariese F, Stroomberg G, van 
den Berg M, Everaarts JM. (2001). Dose- and time-dependent formation of 
biliary benzo[a]pyrene metabolites in the marine fl  atfi  sh dab (Limanda li-
manda). Environ Toxicol Chem 20: 1641–1647.
Wang JJ, Frazer DG, Law B, Lewis DM. (2003). Identifi  cation and quantifi  cation 
of urinary benzo[a]pyrene and its metabolites from asphalt fume exposed 
mic e by microfl  ow L C c oupled t o h ybrid quadrupole time-of -fl  ight mass 
spectrometry. Analyst 128: 864–870.
Wiechelman KJ, Braun RD, Fitzpatrick JD. (1988). Investigation of the bicincho-
ninic acid protein assay: identifi  cation of the groups responsible for color for-
mation. Anal Biochem 175: 231–237.
Zhu S, Li L, Thornton C, Carvalho P, Avery BA, Willett KL. (2008). Simultaneous 
determination of benzo[a]pyrene and eight of its metabolites in Fundulus 
heteroclitus bile using ultra-performance liquid chromatography with mass 
spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 863: 141–149.